Metastasis is altered through multiple processes regulated by the E2F1 transcription factor

Matthew R. Swiatnicki1 & Eran R. Andrechek2*

The E2F family of transcription factors is important for many cellular processes, from their canonical role in cell cycle regulation to other roles in angiogenesis and metastasis. Alteration of the Rb/E2F pathway occurs in various forms of cancer, including breast cancer. E2F1 ablation has been shown to decrease metastasis in MMTV-Neu and MMTV-PyMT transgenic mouse models of breast cancer. Here we take a bioinformatic approach to determine the E2F1 regulated genomic alterations involved in the metastatic cascade, in both Neu and PyMT models. Through gene expression analysis, we reveal few transcriptome changes in non-metastatic E2F1−/− tumors relative to transgenic tumor controls. However, investigation of these models through whole genome sequencing found numerous differences between the models, including differences in the proposed tumor etiology between E2F1−/− and E2F1+/+ tumors induced by Neu or PyMT. For example, loss of E2F1 within the Neu model led to an increased contribution of the inefficient double stranded break repair signature to the proposed etiology of the tumors. While the SNV mutation burden was higher in PyMT mouse tumors than Neu mouse tumors, there was no statistically significant difference between E2F1 WT and E2F1 KO mice. Investigating mutated genes through gene set analysis also found a significant number of genes mutated in the cell adhesion pathway in E2F1−/− tumors, indicating this may be a route for disruption of metastasis in E2F1−/− tumors. Overall, these findings illustrate the complicated nature of uncovering drivers of the metastatic process.

Breast cancer is the most diagnosed cancer in women. To study genomic events contributing to breast cancer, numerous genetically engineered mouse models have been generated, including MMTV-Neu1 which recapitulates HER2+ve breast cancer, and MMTV-Polyoma virus Middle T antigen (PyMT)2. The PyMT model is highly aggressive, with tumors appearing at 45 days of age. Metastasis to the lung occurs in over 90% of tumor bearing mice, resulting in wide use of PyMT for metastasis studies. Similar to human breast cancers, both Neu and PyMT models have striking heterogeneity at histological and gene expression levels3–6, reinforcing the importance of these models as tools for the study of breast cancer.

Previous studies using Neu and PyMT models predicted a key role for the E2F1 transcription factor through a pathway signature analysis, suggesting that mechanisms outside the overexpression of the Neu or PyMT oncogene were contributing to tumor biology7,8. The E2F family of transcription factors is involved in numerous cellular processes, best known for cell cycle control. Usually sequestered by retinoblastoma (Rb), E2F1 is released to act on downstream targets upon Rb phosphorylation9. While mutations in E2F1 are not common in human breast cancer, mutations within the E2F pathway occur in over 25% of breast cancer patients, illustrating the importance of the pathway10–14.

To test the hypothesis that E2F1 regulates key events in Neu and PyMT tumors, E2F1 knockout (KO) mice13 were interbred with Neu and PyMT models7,8. This resulted in mammary tumors with changes in latency, growth rate, and a significant decrease in metastasis to the lung. Metastasis is the ultimate cause of mortality in cancer, with an estimated 90% of cancer deaths resulting from the spread of cancer cells to distal sites within the body15. Typically, cancer cells undergo numerous important steps for completion of the metastatic cascade. These include escape from the primary tumor, intravasation, extravasation, and seeding the distal site16 as reviewed by Welch17.

1Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA. 2Department of Physiology, Michigan State University, 2194 BPS Building, 567 Wilson Road, East Lansing, MI 48824, USA. *email: Andrech1@msu.edu
An important component contributing to the metastatic capability of a tumor is its microenvironment. Various collagens and proteins integral to cellular and tissue structure are capable of impacting metastatic potential. Indeed, proteins within the extracellular matrix, including collagen IV, have been found to regulate metastasis within the liver. Collagen IV is a major component of the basement membrane, an important barrier to tumor invasion and breaching this has been shown to be a critical early step in tumor invasion and metastasis.

Interestingly, a previous report demonstrated a decrease in the number of circulating tumor cells within PyMT E2F1−/− mice, suggesting a disruption to the early steps in the metastatic cascade. Other data shows remodeling of the extracellular matrix at pre-metastatic lesion sites to be important for eventual seeding of distant metastasis.

Recent advances in bioinformatics methods have facilitated the investigation of cancer biology. Publicly available transcriptomic datasets have allowed for comparisons between primary tumor and distant metastatic lesions. Next generation sequencing has furthered our understanding of cancer genomics. Studies involving the sequencing of human tumors have described the mutation rate of solid tumors, and demonstrated that numerous genomic events are required for metastasis. To determine the underlying genomic events behind altered metastatic characteristics in E2F1 KO tumors, gene expression and sequence data was analyzed. Here, we characterize the genome landscape of E2F WT and E2F1 KO tumors from both the Neu and PyMT models and uncover new targets that may be critical to tumor development and progression.

**Results**

We previously demonstrated altered phenotypic characteristics upon ablation of E2F1 within Neu and PyMT models, including changes in growth rate and tumor latency for the primary tumors (Fig. 1A). Given the short latency of PyMT mice, it was surprising to observe tumor latency in PyMT mice significantly decreased with E2F1 loss while growth rate remained unaffected. Interestingly, the opposite effect was seen within Neu E2F1−/− mice, where latency was significantly increased, and growth rate was significantly increased. However, the most striking phenotype was a significant reduction of metastasis with loss of E2F1 in both strains (Fig. 1B and C).

To determine whether gene expression differences regulated phenotypic changes in E2F1 knockout tumors, fold change differences were examined. Volcano plots revealed few genes with a fold change greater than 1.5. To test whether this is recapitulated in human breast cancer, data from The Cancer Genome Atlas (TCGA) was analyzed. E2F1 activity in HER2+ve samples was determined using pathway signature analysis. Samples were stratified into quartiles for E2F1 activity and differential gene expression was determined. As shown in Fig. 2B, human breast tumors resemble mouse mammary tumors in that low E2F1 activity does not lead to vast gene expression changes. To test for genetic pathways affected by loss of E2F1, Gene Set Enrichment Analysis (GSEA) was completed on Neu and PyMT tumors with and without E2F1. GSEA analysis revealed several differentially regulated pathways, including WNT signaling, and nucleotide excision repair (Fig. 2C). Importantly, WNT signaling has been shown to regulate the epithelial to mesenchymal transition, a process involved in the metastatic cascade.

Given that the gene expression analysis did not identify a mechanism altering metastatic potential, we examined genomic events occurring in Neu and PyMT tumors with and without E2F1. Whole genome sequencing was completed and single nucleotide variant (SNV) profiles were called for each tumor using TCGA best practices. Initial analysis of the SNV data resulted in an unexpectedly high proportion of SNVs occurring within chromosome 2 of the E2F1 knockout tumors (Fig. 3A, B). However, E2F1 is located within the qH1 band of chromosome 2 and correlated to where the increased SNVs were observed (Fig. 3C–E). While E2F1 knockout mice were backcrossed 12 generations to FVB, we hypothesized that SNV abundance was caused by residual background strain DNA from the original E2F1 knockout strain. Given that E2F1 mice were generated in the SV129 background, and Neu and PyMT mice are on the FVB background, we filtered SNV calls using a list of SNVs that were generated from comparing the SV129 background against the C57/B6J background, the standard mouse reference genome (Fig. 3F). As a result, the majority of chromosome 2 SNV calls were filtered out, and the proportion of SNVs was roughly equal across the 19 autosomal mouse chromosomes in E2F1 WT and E2F1 KO PyMT tumors (Fig. 3G). This was also the case for E2F1 KO Neu tumors (data not shown). As such, residual background is an important caution when sequencing mouse models.

Interestingly, the SNV mutation burden was higher in PyMT mice as compared to Neu mice (p value = 0.05), which was surprising due to the brief latency of PyMT tumors (Fig. 4A). Except for one PyMT E2F1 knockout tumor, the rate of exonic SNVs ranged from 0.005 to 0.08 mutations per megabase. This mutation rate is similar to previous rates shown for mouse tumors, and is lower than the 1 mutation / megabase exonic mutation rate commonly observed in human breast cancer.

To analyze distinct types of SNVs occurring within our tumors, and investigate potential mechanisms driving these differences, a mutation signature approach was taken. While trinucleotide signatures showed similarities between Neu and PyMT tumors, there were striking differences, such as T > G mutations occurring almost exclusively in Neu tumors of either E2F1 status (Fig. 4B). The signatures for all 12 tumors are shown in Supplemental Figure 1. Principal component analysis (PCA) completed using mutation signatures from all 12 tumors shows distinct clustering between Neu and PyMT tumors (Fig. 4C). Furthermore, apart from a single E2F1 KO PyMT tumor, PCA separates E2F1 WT and E2F1 KO tumors into distinct clusters within the Neu and PyMT models. While PyMT E2F1 KO sample 2 has a sixfold increase in the number of SNVs, this is not reflected within the sample clustering of the principal component analysis. This is due to PCA being completed on the mutation signatures of the samples. For example, if sample X were to have an increased number of SNVs as compared to sample Y, but the overall mutation profile of those SNVs was similar between sample X and Y, they would cluster together.
The contribution of the 30 known COSMIC (catalog of somatic mutations in cancer) signatures to each Neu and PyMT tumor were then determined. While all Neu and PyMT tumors had some contribution from signature 18, there were stark differences in other COSMIC signatures contributing to Neu and PyMT tumors.

**Figure 1.** Altered phenotypic characteristics in E2F1−/− tumors. (A) E2F1−/− mice were crossed with MMTV-Neu and MMTV-PyMT mice on the FVB background to create E2F1 knockouts in both models. (B) Phenotypic changes seen in PyMT E2F1−/− mice and (C) Neu E2F1−/− mice, summarizing changes in latency, growth rate, and number of metastasis. H&E staining of E2F1+/+ mouse lung shows a large number of metastasis, while E2F1−/− mice have little to no metastasis. Histology of the lungs was obtained at primary tumor endpoint.
Figure 2. Gene expression changes in E2F1−/− mouse tumors, and E2F1 low human breast cancer. (A) Two volcano plots show significant fold changes in genes from Neu and PyMT mouse tumors respectively. Fold change was determined by subtracting the E2F1 KO mean from the E2F1 WT mean for each gene. Fold change and p value cutoff for Neu tumors was .5, and .05 respectively. Fold change and p value for PyMT tumors was 1.0 and .001 respectively. (B) Diagram represents data processing steps for human TCGA data. A volcano plot shows significant fold change genes in E2F1 high versus E2F1 low human HER2+ve tumors. Fold change was determined by subtracting samples in the lowest E2F1 quartile mean from the highest E2F1 quartile mean for each gene. Fold change cutoff and p value for human tumors was 2.0, and 10e−60 respectively. (C) GSEA plots generated for E2F1 WT versus E2F1 KO tumors (Neu and PyMT combined) show enrichment of Nucleotide excision repair, and WNT signaling pathways in E2F1 KO tumors.
Figure 3. Filtering background strain to remove artifacts that have potential to confound analysis. (A) Pie chart from an E2F1+/+ PyMT tumor represents the normalized (SNVs/chromosome size) percentage of SNVs within each chromosome. (B) Pie chart from an E2F1−/− PyMT tumor represents the normalized percentage of SNVs within each chromosome. An abundance of SNVs within chromosome 2 is observed. (C) The banding pattern of mouse chromosome 2. The arrow highlights the location of E2F1, and the yellow box represents the bands represented in (D) and (E). (D) Manhattan plot shows the number of SNVs occurring within the 2qF3–2qH3 bands of chromosome 2, in the E2F1+/+ sample from (A). (E) Manhattan plot shows the number of SNVs occurring within the 2qF3–2qH3 bands of chromosome 2, in the E2F1−/− sample from (B). (F) Top pie chart is the same as in (B). Bottom pie chart represents the percentage of SNVs across each chromosome of the same sample as above, after filtering on the sv129 background.
Figure 4. SNV mutation burden in Neu and PyMT tumors. (A) Bar graphs represent the number of total or exonic mutations per megabase occurring in all 12 sequenced tumors. (B) Shows representative mutation profiles for each of the four classes of samples sequenced. Mutation profiles are derived from 96 bp trinucleotide signatures originally developed by Alexandrov et al. Four classes of samples are Neu E2F1+/+, Neu E2F1−/−, PyMT E2F1+/+, PyMT E2F1−/−. (C) PCA plots derived from trinucleotide signatures show clustering of all 12 samples sequenced. (D) The heatmap of cancer signatures for the 12 sequenced tumors, as well as various cancers is shown.
taken using Gather. First, genes with potentially impactful mutations were stratified into two gene lists that
within particular pathways comparing E2F1 knockout to wildtype tumors, a database mining approach was
were mutated exclusively within E2F wildtype tumors. To identify whether an abundance of mutations occurred
Table 2 have known metastatic implications, they were not consistently mutated within the sample groups, or
in a number of cancer associated genes (Supplemental Table 2). While a few of the genes listed in Supplemental
of the translocations were predicted to be real events.
the breakpoint, confirming the existence of the translocation (Fig. 6). Based on this evidence, upwards of 80%
completed with primers flanking the translocation junction. Both translocated and wild type reads were present at
normal tissue when primary tumor was collected for sequencing, and since the abundance of wild type reads
fairly large for many of the translocation sites, this suggests a large amount of heterogeneity within the tumors.
all translocation events analyzed had a varying level of wild type reads present. Since care was taken to exclude
normal tissue (vasculature, immune etc.) is present in any tumor, the prevalence of wild type reads is
is far below that observed for mutations. To verify one of the translocation events from Table 1, PCR was com-
while, relatively few larger events (above 1 mb) were observed. Surprisingly, there was a large amount of copy number gene overlap between the E2F WT and E2F1 KO tumors (Fig. 5E). The large number of shared genes involved in copy number events may indicate E2F1 loss is not a
primary driver of these events.
There were also a surprisingly large number of translocations occurring within the Neu and PyMT tumors.
When comparing average number of translocations per sample across the genomic models, there were statistic-
cally more translocations occurring within Neu tumors than PyMT tumors, regardless of E2F1 status. When
comparing E2F1 status within each model, there was no statistically significant difference (Fig. 5F). To confirm
the translocation calls made by Delly and Lumpy, 20 translocations from each tumor were chosen at random
and read evidence for these translocations was analyzed using Genome Ribbon43. Translocation read data for
one tumor is shown in Table 1. All tumors had at least 75% of translocations with some read support, with 9 of
12 tumors having at least 85% of translocations with some read support (Supplemental Table 1). Interestingly,
all translocation events analyzed had a varying level of wild type reads present. Since care was taken to exclude
normal tissue when primary tumor was collected for sequencing, and since the abundance of wild type reads is
fairly large for many of the translocation sites, this suggests a large amount of heterogeneity within the tumors.
While some normal tissue (vasculature, immune etc.) is present in any tumor, the prevalence of wild type reads is
far below that observed for mutations. To verify one of the translocation events from Table 1, PCR was com-
pleted with primers flanking the translocation junction. Both translocated and wild type reads were present at the
breakpoint, confirming the existence of the translocation (Fig. 6). Based on this evidence, upwards of 80% of
the translocations were predicted to be real events.
To determine whether cancer and metastasis related genes were mutated within E2F1 WT and E2F1 KO
tumors, the mutation list was filtered with known cancer genes from COSMIC. This analysis found mutations
in a number of cancer associated genes (Supplemental Table 2). While a few of the genes listed in Supplemental
Table 2 have known metastatic implications, they were not consistently mutated within the sample groups, or
were mutated exclusively within E2F wildtype tumors. To identify whether an abundance of mutations occurred
within particular pathways comparing E2F1 knockout to wildtype tumors, a database mining approach was
taken using Gather33. First, genes with potentially impactful mutations were stratified into two gene lists that
were distinct in E2F1−/− and E2F1+/+ tumors. Potentially impactful mutations included SNVs causing stop gain
mutations within PyMT E2F1 KO tumors. Other mutations within PyMT E2F1 KO tumors include COL5A2, with collagen V being a component of the interstitial
matrix, COL6A1-3, with collagen VI being abundant in the tumor invasive front13-15 and several integrin and
cadherin genes. Interestingly, a closer examination of the gene expression data revealed the integrin pathway
was also found to be upregulated within E2F WT tumors, but not E2F1 KO tumors (Supplemental Tables 3, 4).
There was also an abundance of intronic and synonymous mutations within these genes, suggesting they may
be hypermutated due to the disruption of E2F1 within the model, although this hasn't been statistically verified.
Indeed, of the 64 mutated genes within the cell adhesion Gene Ontology number 0007155, half were noted to
have an E2F1 binding motif using TRANSFAC (p value = 0.003, data not shown). With E2F1 known to regulate
the cell cycle as well as a number of genes involved in DNA repair and adhesion, it is feasible that loss of E2F1
could result in an abundance of mutations within certain gene profiles through a disruption of the cell's ability
to undergo DNA repair during the S phase. E2F1 loss and corresponding disruptions to the cell cycle, especially
during S phase could conceivably lead to an increased mutation burden, potentially within E2F regulated genes.
E2F1 has also been shown to recruit nucleotide excision repair and double stranded break repair factors to sites
of DNA damage. It is possible that loss of recruitment of these factors could lead to inefficient DNA repair, and an increased mutational burden, although this would need to be further explored.

**Discussion**

Ablation of E2F1 in PyMT and Neu transgenic mice results in a significant decrease in pulmonary metastasis. To determine whether gene expression changes were responsible for altered phenotypes, transcriptomic data was analyzed but showed no large changes in gene expression between E2F1+/+ and E2F1−/− tumors. This was recapitulated in human HER2+ breast cancers after separation into E2F1 high/low quartiles. GSEA revealed several pathways differentially regulated between E2F1+/+ and E2F1−/− tumors, but without obvious implications in regulating metastasis. To test for genomic alterations impacting metastasis, we completed WGS of E2F1+/+ and E2F1−/− tumors in Neu and PyMT models. Mutation trinucleotide signatures showed differences between etiology of Neu and PyMT tumors, as well as between the E2F1 knockout and WT tumors. Neu tumors were more closely associated with double stranded break repair, while PyMT tumors were associated with DNA Mismatch Repair. As noted, Neu E2F1 KO tumors were more closely associated with defective double stranded break repair than Neu E2F wildtype tumors. An interesting question that warrants further investigation would be whether this was due to increased alterations within these genes upon loss of E2F1, or due to some other transcriptional function of E2F1. Analyzing mutated genes for GO and KEGG pathways revealed alterations in cell adhesion. Further analysis of these genes uncovered a role in the basement membrane and interstitial matrix, which could be a potential mechanism for disruption of the metastatic cascade.
Sequencing data from genetically engineered mouse models is largely lacking, with only a few models having been sequenced. SNV mutation rates between previous studies and ours indicate similarities, and small discrepancies may be explained through differences in data processing methods. For copy number variation prior research has shown numerous small copy number events and a few larger events, although this was estimated from whole exome sequencing data. This was recapitulated in our data, with the exception that large events were not prevalent after taking the consensus of two structural variant callers. We also noted a substantially greater number of translocations within the mouse tumors as compared to a previous study comparing Neu and PyMT wildtype tumors, while the same trend of Neu tumors having more translocations than PyMT tumors held. This increase in called translocations is likely due to differences in calling methods. Overall, the field would benefit from a large comparison of mouse tumor sequencing data with tumors analyzed under the same parameters.

After analyzing mutated genes using a pathway approach, many genes involved in cell adhesion were found having potentially impactful mutations in E2F1 knockout tumors, but not E2F1 wild type tumors, including various collagens, integrins and cadherins. Of the mutated genes found important to cell adhesion, genes such as Col4a1 are important components of the basement membrane and are involved in tumor progression. Disruptions to the basement membrane and collagen formation has potential to disrupt the metastatic process. This theory is supported by previous data we generated, which found a significant decrease in circulating tumor cells. Interestingly, we have also previously noted amplification of Col1a1 in Neu E2F1 WT tumors which impacted the metastatic process. Combined, these data suggest collagens and proteins within the basement membrane are important to the metastatic process in Neu and PyMT tumors.

SNV profiling for human tumors has utility for both discovery and treatment purposes. Sequencing of human breast tumors has revealed larger genomic trends as well as mutation rates for oncogenes and tumor suppressors. Potential sources of error when determining SNVs can stem from differing genetic background within mice, even after backcrossing, as well as being too loose or too stringent with the filtering process. Interestingly, our prior work identified and validated a SNV in Ptprh in PyMT tumors, but this mutation was not present within this sequence analysis. While the initial paper stipulated an SNV call must pass 3 of 4 SNV calling programs, the work herein stipulated a call must pass 3 of 3 programs used, leading to the discrepancy. When analyzing the SNV data for each program used, a Ptprh SNV was called from SomaticSniper and Varscan, but not called from MuTect2. This suggests the usage of multiple programs to call SNVs is more applicable for discovery purposes, and that less stringent filtering parameters may be beneficial.

When analyzing copy number alterations and translocations within the models, there were a surprising lack of differences across E2F1 status, suggesting E2F1 loss is not a primary driver of these events. Furthermore, the varying read support seen for confirmed translocations indicates a high amount of tumor heterogeneity occurring in both models, regardless of E2F1 status. While there were numerous COSMIC associated genes mutated within the models, no mutations conserved between E2F1 knockout tumors (within or across models) were immediately apparent as important to the metastatic process.

| Translocation # | Position 1 | Position 2 | Supporting reads (approximate) | Total reads (exact) | % Support |
|----------------|------------|------------|-------------------------------|---------------------|-----------|
| 1              | 3_65552053 | 2_20941004 | 10                            | 61                  | 16.39     |
| 2              | 2_161669843| 18_78292047| 10                            | 119                 | 8.40      |
| 3              | 15_43944218| 1_112318855| 6                             | 89                  | 6.74      |
| 4              | 13_23307876| 11_88303305| 11                            | 104                 | 10.58     |
| 5              | 5_5609182  | 18_56166475| 14                            | 77                  | 18.18     |
| 6              | 5_7058436  | 2_8931319  | 4                             | 49                  | 8.16      |
| 7              | 16_83532604| 14_96841358| 15                            | 83                  | 18.07     |
| 8              | 5_153288050| 17_10818207| 15                            | 88                  | 17.05     |
| 9              | 16_83532819| 14_96841377| 19                            | 94                  | 20.21     |
| 10             | 16_18368004| 12_80665928| 10                            | 85                  | 11.76     |
| 11             | 8_102861241| 17_67932443| 0                             | 57                  | 0.00      |
| 12             | 14_21312516| 11_9863013 | 16                            | 234                 | 6.84      |
| 13             | 9_55224433 | 8_85188141 | 13                            | 82                  | 15.85     |
| 14             | X_38480149 | 9_55983052 | 12                            | 70                  | 17.14     |
| 15             | 6_73162349 | 16_96121815| 3                             | 34                  | 8.82      |
| 16             | 4_43262573 | 3_113857214| 4                             | 68                  | 5.88      |
| 17             | 5_62573934 | 13_86796353| 2                             | 77                  | 2.60      |
| 18             | 3_135929185| 1_139635092| 9                             | 95                  | 9.47      |
| 19             | 6_67680744 | 4_147419479| 0                             | 158                 | 0.00      |
| 20             | 7_79199005 | 19_40536086| 14                            | 81                  | 17.28     |

Table 1. Supporting reads for 20 randomly selected translocations from the tumor in Fig. 6. Random translocations were selected by inputting all translocations from the tumor into Excel, and using the RAND() function to assign a random number. The 20 highest translocations were then selected. Positions 1 and 2 represent the translocation breakpoint. Genome Ribbon was used to analyze read evidence.
Figure 6. Verification of translocation calls. (A) Example of a GenomeRibbon plot where no structural variation occurs. The top colored bands represent each chromosome of the mouse, and the red box below represents the location searched within a sample's bam file. Each line within that box represents a different read. (B) A GenomeRibbon plot representing translocation number 13 from Table 1. Translocated reads are shown between chromosome 9 and chromosome 8. (C) Gel image of the chromosome 8/9 translocation from the GenomeRibbon plot above. DNA was from a PyMT E2F1−/− tumor. Both translocation and wild type tumor DNA were amplified. Translocated reads were amplified using a primer set flanking the region where the two translocated ends ligate. Gel image is cropped to remove excess, see supplemental for full gel.
Analyzing gene expression changes between E2F1 WT and E2F1 KO tumors showed no major changes upon E2F1 loss. This was recapitulated among human HER2+ve breast cancer tumors stratified between low and high E2F1 activity. The lack of large gene expression changes may indicate that numerous small changes result in phenotypic alterations, or that genomic mutations are leading to altered protein function/localization. Interestingly, the gene encoding Transcription Factor AP-2 Beta was significantly upregulated in Neu E2F1 KO mice. This, combined with the data showing a lack of major gene expression changes between E2F1 WT and E2F1 KO tumors, indicates some possible compensation by Transcription Factor AP-2 Beta, as well as other members of the E2F family. The sequencing data from E2F1−/− Neu and PyMT mice indicate phenotypic changes may be due to an abundance of mutations in particular pathways, in addition to minor expression changes. Taking into consideration that the metastatic process likely originates from a small population of metastatic cells within the primary tumor, the contribution of a few metastatic cells to the bulk tumor gene expression or sequencing data may cause key events to be lost within the noise of the primary tumor. Future work will address these issues through single cell sequencing and gene expression in matched primary and metastatic tumors.

Methods

Animal models. No live animals were directly used for this study. Gene expression and sequencing data was obtained previously. In those studies, all methods involving animals were carried out in accordance with relevant guidelines and regulations. All experimental protocols involving animals in the previous studies were approved through Michigan State University.

Gene expression analysis. Gene expression data was described previously. Volcano plots for Neu and PyMT tumors were generated by removing outliers for each sample group using Nowaclean (Holsb, Einar. 2017. “nowaclean”), samples greater than 3.0 standard deviations away when constructing PCA plots were removed. Data were log2 transformed, and the mean for each gene was calculated within the four sample groups. Fold change was calculated by subtracting the E2F1 KO mean from the E2F1 WT mean for each gene. P values were calculated and data plotted using EnhancedVolcano (Blighle, Kevin. 2018. “EnhancedVolcano”) in R. Human RSEM normalized RNAseq breast cancer data from TCGA was downloaded from UCSC Xena, filtered to

Figure 7. Mutations in basement membrane genes. Diagram shows various mutations occurring in genes that code for proteins making up the basement membrane and interstitial matrix. Circles at top indicate genes with colors representing 1 of 3 sequenced E2F1−/− PyMT tumors that has a mutation in that gene. Image on left represents a breast tumor with surrounding basement membrane. Image on right represents the basement membrane and interstitial matrix on the outer edge of a tumor.
HER2+ samples, and sorted by E2F1 expression. Lower and upper quartiles were kept and data were processed for volcano plots as above. GSEA plots were generated from combining Neu and PyMT gene expression datasets. Datasets were collapsed and combatted to remove batch effects. GSEA was run using GenePattern41.

Whole genome sequencing and processing. Raw whole genome sequencing data from mouse tumors was previously obtained46. Briefly, three samples from each group (total of 12) were used, DNA from flash frozen extracted following manufacturer’s protocol for Qiagen Genomic-tip 20/G kit. Sequencing was completed at a depth of 40× with paired end, 150 base pair reads. DNA was prepared and sequenced using Illumina TrueSeq Nano DNA library preparation and an Illumina HiSeq 2500. For this study, raw fastq files were assessed for quality control using FASTQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and trimmed using Trimmomatic41. Files were aligned to mm10 mouse reference using BWA MEM42 with standard parameters. Picard tools (“Picard Toolkit. ” 2019) was used to add read groups and remove duplicates. Samtools43 was used to sort and index files.

Variant calling. Somatic SNVs were called using SomaticSniper44, Mutect245, and VarScan46. Consensus calls were merged using R (R Core Team (2018)) base programming, and mutations were only kept if called by all three programs. SNV calls were filtered using base R to account for differences between the FVB strain and mm10 alignment (C57/BL6), as well as differences between the SV129 strain (original E2F1 mouse background) and C57/BL6. SNVs were annotated using AnnoNov47. CNVs were determined by keeping the consensus of Lumpy48 and Delly49. Consensus was determined using Intansv (Yao W 2019) at a threshold of 0.2, and events smaller than 10,000 bp were filtered out. Intansv was also used to annotate CNV events. Translocations were called using Lumpy and Delly, and filtered based on read evidence. Lumpy calls were kept if they had at least 20 supporting split end and paired end reads, Delly calls were kept if there was split end and paired end read evidence for the call. WT FVB mouse sequence was used as a normal control.

Mutation signatures. Trinucleotide mutation signatures were completed using the Musica50 shiny app in R. Musica code was altered to allow for the use of the mouse mm10 reference genome.

Circos plots. Circos plots were generated for each sample using CIRCOS version 0.6951. Genetic variants were plotted according to the mm10 reference genome.

Translocation verification. Read evidence for 20 randomly selected translocations from all 12 sequenced samples was examined using GenomeRibbon52. For PCR verification, primers were designed with at least 400 bp flanking the predicted breakpoint.

Received: 4 March 2020; Accepted: 5 April 2021
Published online: 04 May 2021

References
1. Guy, C. T. et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. 89, 10578–10582 (1992).
2. Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954–961 (1992).
3. Cardiff, R. D. et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19, 968–988 (2000).
4. Herschkowitz, J. I. et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76 (2007).
5. Hollern, D. P. & Andrechek, E. R. A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res. 16, 1–16 (2014).
6. Hollern, D. P., Swiatnicki, M. R. & Andrechek, E. R. Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers. PLoS Genet. 14, e1007133 (2018).
7. Hollern, D. P., Honeysett, J., Cardiff, R. D. & Andrechek, E. R. The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol. Cell. Biol. 34, 3229–3243 (2014).
8. Andrechek, E. R. HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors. Oncogene https://doi.org/10.1038/onc.2013.540 (2015).
9. Nevins, J. R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (80-) 258, 424–429 (1992).
10. Gorgoulis, V. G. et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J. Pathol. 198, 142–156 (2002).
11. Qin, G. et al. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. PNAS 18, 11015–11020 (2006).
12. Rosaud, F. et al. E2F1 inhibition mediates cell death of metastatic melanoma. Cell Death Dis. 9, 1–12 (2018).
13. Field, S. J. et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85, 549–561 (1996).
14. Cancer Genome Atlas Research Network et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).
15. Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559–1564 (2011).
16. Fuller, J. I. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3, 453–458 (2003).
17. Welch, D. R. & Hurst, D. R. Defining the hallmarks of metastasis. Can. Res. 79, 3011–3027 (2019).
18. Burnier, J. V. et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene 30, 3766–3783 (2011).
19. Chang, T. T., Thakar, D. & Weaver, V. M. Force-dependent breaching of the basement membrane. Matrix Biol. 57–58, 178–189 (2017).
20. Walker, C., Mojares, E. & del Río Hernández, A. Role of extracellular matrix in development and cancer progression. Int. J. Mol. Sci. 19, 3028 (2018).
21. Cox, T. R. et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522, 106–110 (2015).
22. Daves, M. H., Hilsenbeck, S. G., Lau, C. C. & Man, T. K. Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med. Genom. 4, 1–14 (2011).
23. Cosphidi, I. et al. Bone metastasis in advanced breast cancer: analysis of gene expression microarray. Clin. Breast Cancer 18, e1117–e1122 (2018).
24. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
25. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005 (2010).
26. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
27. Navin, N. et al. Tumor evolution inferred by single-cell sequencing. Nature 472, 90–95 (2011).
28. Wu, Y. et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol. Cancer Res. 10, 1597–1606 (2012).
29. Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. Oncogene 36, 1461–1473 (2017).
30. Rennhack, J. P. et al. Integrated analyses of murine breast cancer models reveal critical parallels with human disease. Nat. Commun. 10, 3261 (2019).
31. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
32. Chen, J. et al. EZF1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks. Cell Cycle 10, 1287–1294 (2011).
33. Chang, J. T. & Nevin, J. R. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22, 2926–2933 (2006).
34. Choi, E. H. & Kim, K. P. EZF1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp. Mol. Med. 51, 1–12 (2019).
35. Guo, R. et al. EZF1 localizes to sites of UV-induced DNA damage to enhance nucleotide excision repair. J. Biol. Chem. 285, 19308–19315 (2010).
36. McFadden, D. G. et al. Mutational landscape of EGFR-, MYC-, and Kras- driven genetically engineered mouse models of lung adenocarcinoma. Proc. Natl. Acad. Sci. 113, E6409–E6417 (2016).
37. Francis, J. C. et al. Whole-exome DNA sequence analysis of BrcA2- and Trp53- deficient mouse mammary gland tumours. J. Pathol. 236, 186–200 (2015).
38. Campbell, K. M. et al. A spontaneous aggressive ERα+ mammary tumor model is driven by Kras activation. Cell Rep. 28, 1526–e4-1537.e4 (2019).
39. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012).
40. Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500–501 (2006).
41. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
42. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM (2013).
43. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
44. Larson, D. E. et al. Somaticsniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311–317 (2012).
45. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
46. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
47. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucl. Acids Res. 38, e164 (2010).
48. Layer, R. M., Chiang, C., Quinlan, A. R. & Hall, I. M. LUMPY: a probabilistic framework for structural variant discovery. Genome Biol. 15, R84 (2014). https://arxiv.org/abs/1303.3997
49. Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, 333–339 (2012).
50. Diaz-Gay, M. et al. Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples. BMC Bioinform. 19, 224 (2018).
51. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639–1645 (2009).
52. Natestad, M., Chin, C.-S. & Schatz, M. C. Ribbon: visualizing complex genome alignments and structural variation. bioRxiv 0344, 82123 (2016).

Author contributions
M.S. performed all experiments, M.S. and E.R.A. contributed to experimental design and drafting the manuscript.

Funding
This work was supported with NIH R01CA160514 and Worldwide Cancer Research WCR - 14-1153 to ERA.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-88924-y.

Correspondence and requests for materials should be addressed to E.R.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
